Correlation Between Pharmacyclics and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pharmacyclics and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharmacyclics and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pharmacyclics and Novo Nordisk AS, you can compare the effects of market volatilities on Pharmacyclics and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharmacyclics with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharmacyclics and Novo Nordisk.

Diversification Opportunities for Pharmacyclics and Novo Nordisk

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Pharmacyclics and Novo is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Pharmacyclics and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Pharmacyclics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharmacyclics are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Pharmacyclics i.e., Pharmacyclics and Novo Nordisk go up and down completely randomly.

Pair Corralation between Pharmacyclics and Novo Nordisk

If you would invest  0.00  in Pharmacyclics on January 24, 2024 and sell it today you would earn a total of  0.00  from holding Pharmacyclics or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy5.0%
ValuesDaily Returns

Pharmacyclics  vs.  Novo Nordisk AS

 Performance 
       Timeline  
Pharmacyclics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Pharmacyclics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Pharmacyclics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Novo Nordisk AS 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Novo Nordisk displayed solid returns over the last few months and may actually be approaching a breakup point.

Pharmacyclics and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pharmacyclics and Novo Nordisk

The main advantage of trading using opposite Pharmacyclics and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharmacyclics position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Pharmacyclics and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bonds Directory
Find actively traded corporate debentures issued by US companies
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing